Aug 2026· Leukemia and Lymphoma· pp.
1-19
· 0 citations· 88 references
Medicine
TL;DR
Given its expression pattern, along with its swift internalization and limited expression in most normal tissues, CD74 emerges as a promising target for a wide array of therapeutic approaches like antibody-drug conjugates (ADCs), bispecific antibodies, and Chimeric Antigen Receptor T-cell (CAR-T) therapy.
Abstract
CD74, originally known as the invariant chain of Major Histocompatibility Complex Class II Molecules (MHC class II), has now been acknowledged as a versatile signaling nexus and a universal lymphoma antigen. It has a pivotal role in the maturation, stimulation, and viability of various immune cells, such as B cells, T cells, Regulatory T Cells (Tregs), monocytes, and macrophages. It is extensively and significantly expressed in a variety of hematologic cancers, encompassing acute and chronic leukemias, lymphomas, and multiple myeloma. Given its expression pattern, along with its swift internalization and limited expression in most normal tissues, CD74 emerges as a promising target for a wide array of therapeutic approaches like antibody-drug conjugates (ADCs), bispecific antibodies, and Chimeric Antigen Receptor T-cell (CAR-T) therapy. However, the downstream signaling network of CD74 is highly context-dependent, playing a dual role in physiological immune regulation and pathological pro-cancer survival.
Recent work on anti-CD6 as a candidate immunotherapy for cancer as well as relevant advances in the understanding of other aspects of the biology of CD6 are described and the possibility that this approach could avoid the autoimmune complications that are encountered with checkpoint inhibitor treatment of cancer is exp...
David A. Fox, Mikel Gurrea-Rubio· Frontiers in Immunology· 0 citations
The biology, disease-associated functions, and therapeutic targeting of nonclassical MHC-I molecules are synthesized, integrating immune checkpoint blockade, antibody-based therapeutics, and MR1- and CD1-restricted cellular immunotherapies into a unified framework.
Current findings position B7-H6 as a promising immuno-oncologic target at the intersection of immune surveillance, immune escape, and malignant progression, warranting continued investigation as a next-generation therapeutic axis in cancer immunotherapy.
Ziyi Yang, Qi Zhao· Cancer Biome and Targeted Th...· 0 citations
Diffuse large B-cell lymphoma (DLBCL) is treated with an expanding range of antibody- and cell-based therapies, yet macrophage phagocytosis checkpoints are still often discussed one molecule at a time. Here, we ask how far the evidence for each major axis has actually progressed in DLBCL immunotherapy. We considered fi...
Sha-Sha Qi, Lun-Yao-Dong-Yan Deng, Shan Luo et al.· Frontiers in Oncology· 0 citations
A humanized CD70-targeted CAR-T cell therapy is developed, A174-hu1-CAR-T, with reduced fratricide and potent antitumor activity, providing a preclinical foundation to support further translational development.
Meng-Jia Zhang, Zhi-Hao Wang, Cheng Gao et al.· International Immunopharmaco...· 1 citation
The structure, function, and receptor interactions of CD155 (PVR), with a particular focus on its immunoregulatory role in the ovarian tumor microenvironment are reviewed.
Ming-Yao Huang, Jia-Hui Zhang, Hui-Yan Huang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.